Difference between revisions of "Ibrutinib (Imbruvica)"
Jump to navigation
Jump to search
(updated content) |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Irreversible inhibitor of Bruton's tyrosine kinase (BTK), which is an enzyme that participates in the B-cell receptor (BCR) signal cascade. BCR signaling is believed to promote cell proliferation, adhesion, and survival in B-cell malignancies. Inhibition of BTK interferes with the processes above and | + | Class/mechanism: Irreversible inhibitor of Bruton's tyrosine kinase (BTK), which is an enzyme that participates in the B-cell receptor (BCR) signal cascade and cytokine receptor pathways. BCR signaling is believed to promote cell proliferation, adhesion, and survival in B-cell malignancies. Inhibition of BTK interferes with the processes above, as well as B-cell chemotaxis and trafficking.<ref name=insert>[http://www.imbruvica.com/downloads/Imbruvica_Prescribing_Information_PPI.pdf Ibrutinib (Imbruvica) package insert]</ref><ref>[[Media:Ibrutinib.pdf | Ibrutinib (Imbruvica) package insert (locally hosted backup)]]</ref><ref>[http://www.imbruvica.com/ Imbruvica manufacturer's website]</ref> |
| − | <br>Route: PO | + | <ref>[http://www.pharmacyclics.com/productpipeline1.html Pharmacyclics BTK inhibitor website]</ref><br>Route: PO |
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 11: | Line 11: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | + | *[http://www.imbruvica.com/downloads/Imbruvica_Prescribing_Information_PPI.pdf#page=18 Ibrutinib (Imbruvica) package insert PDF pages 18-19]<ref name="insert"></ref> | |
| + | *[http://chemocare.com/chemotherapy/drug-info/ibrutinib.aspx Ibrutinib (Imbruvica) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/ibrutinib.aspx Ibrutinib (Imbruvica) patient drug information (Chemocare)]</ref> | ||
| + | *[http://www.uptodate.com/contents/ibrutinib-patient-drug-information Ibrutinib (Imbruvica) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ibrutinib-patient-drug-information Ibrutinib (Imbruvica) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *11/13/2013: | + | *11/13/2013: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm374857.htm FDA granted accelerated approval] "for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy." |
| − | *2/12/2014: | + | *2/12/2014: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm385878.htm FDA granted accelerated approval] "for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy." |
==Also known as== | ==Also known as== | ||
| Line 23: | Line 25: | ||
<references/> | <references/> | ||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
[[Category:BTK inhibitors]] | [[Category:BTK inhibitors]] | ||
| + | [[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | ||
| + | [[Category:Mantle cell lymphoma medications]] | ||
| + | [[Category:Drugs FDA approved in 2013]] | ||
Revision as of 00:01, 16 February 2014
General information
Class/mechanism: Irreversible inhibitor of Bruton's tyrosine kinase (BTK), which is an enzyme that participates in the B-cell receptor (BCR) signal cascade and cytokine receptor pathways. BCR signaling is believed to promote cell proliferation, adhesion, and survival in B-cell malignancies. Inhibition of BTK interferes with the processes above, as well as B-cell chemotaxis and trafficking.[1][2][3]
[4]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Ibrutinib (Imbruvica) package insert PDF pages 18-19[1]
- Ibrutinib (Imbruvica) patient drug information (Chemocare)[5]
- Ibrutinib (Imbruvica) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 11/13/2013: FDA granted accelerated approval "for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy."
- 2/12/2014: FDA granted accelerated approval "for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy."
Also known as
PCI-32765
References
- ↑ 1.0 1.1 1.2 Ibrutinib (Imbruvica) package insert
- ↑ Ibrutinib (Imbruvica) package insert (locally hosted backup)
- ↑ Imbruvica manufacturer's website
- ↑ Pharmacyclics BTK inhibitor website
- ↑ Ibrutinib (Imbruvica) patient drug information (Chemocare)
- ↑ Ibrutinib (Imbruvica) patient drug information (UpToDate)